Silvio Traversa
Director Técnico/Científico/I+D en SIENNA BIOPHARMACEUTICALS, INC. .
Cargos activos de Silvio Traversa
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/12/2016 | - |
Historial de carrera de Silvio Traversa
Antiguos cargos conocidos de Silvio Traversa.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Director Técnico/Científico/I+D | 01/10/2007 | 01/12/2016 |
| Corporate Officer/Principal | 01/02/2005 | 01/10/2007 | |
| Industria Farmaceutica Serono SpA | Corporate Officer/Principal | - | - |
Formación de Silvio Traversa.
| University of Turin | Doctorate Degree |
| Harvard Business School | Graduate Degree |
Estadísticas
Internacional
| Italia | 4 |
| Estados Unidos | 3 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
| Industria Farmaceutica Serono SpA | |
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
- Bolsa de valores
- Insiders
- Silvio Traversa
- Experiencia
